Login / Signup

Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth.

Katelyn L DonahueHannah R WatkoskePadma KadiyalaWenting DuKristee L BrownMichael K ScalesAhmed M ElhossinyCarlos E EspinozaEmily L Lasse OpsahlBrian D GriffithYukang WenLei SunAshley Velez-DelgadoNur M RenolletJacqueline MoralesNicholas M NedzeskyRachael K BaliiraRosa E MenjivarPaola I Medina-CabreraArvind RaoBenjamin L AllenJiaqi ShiTimothy L FrankelEileen S CarpenterFilip BednarYaqing ZhangMarina Pasca Di Magliano
Published in: Cancer discovery (2024)
Pancreatic cancer is characterized by an extensive fibroinflammatory microenvironment. During carcinogenesis, normal stromal cells are converted to cytokine-high cancer associated fibroblasts (CAFs). The mechanisms underlying this conversion, including regulation and function of fibroblast-derived cytokines, are poorly understood. Thus, efforts to target CAFs therapeutically have so far failed. Here, we show that signals from epithelial cells expressing oncogenic KRAS -a hallmark pancreatic cancer mutation- activate fibroblast autocrine signaling, which drives expression of the cytokine interleukin-33 (IL-33). Stromal IL-33 expression remains high and dependent on epithelial KRAS throughout carcinogenesis; in turn, environmental stress induces IL-33 secretion. Using compartment-specific IL-33 knockout mice, we observed that lack of stromal IL-33 leads to profound reprogramming of multiple components of the pancreatic tumor microenvironment, including CAFs, myeloid cells and lymphocytes. Notably, loss of stromal IL-33 leads to an increase in CD8+ T cell infiltration and activation, and, ultimately, reduced tumor growth.
Keyphrases